175 related articles for article (PubMed ID: 35059985)
21. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
23. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
24. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
[TBL] [Abstract][Full Text] [Related]
25. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
26. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.
Liu H; Naxerova K; Pinter M; Incio J; Lee H; Shigeta K; Ho WW; Crain JA; Jacobson A; Michelakos T; Dias-Santos D; Zanconato A; Hong TS; Clark JW; Murphy JE; Ryan DP; Deshpande V; Lillemoe KD; Fernandez-Del Castillo C; Downes M; Evans RM; Michaelson J; Ferrone CR; Boucher Y; Jain RK
Clin Cancer Res; 2017 Oct; 23(19):5959-5969. PubMed ID: 28600474
[No Abstract] [Full Text] [Related]
27. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
28. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
Tomimaru Y; Eguchi H; Shimomura Y; Kitamura T; Inoue Y; Nagakawa Y; Ohba A; Onoe S; Unno M; Hashimoto D; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Uemura K; Kimura Y; Satoi S; Takeyama Y;
J Gastroenterol; 2023 Aug; 58(8):790-799. PubMed ID: 37329351
[TBL] [Abstract][Full Text] [Related]
29. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
30. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
32. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
33. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
34. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma.
Liu WS; Feng YX; Li SN; Shao YJ; Wang K
Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559
[TBL] [Abstract][Full Text] [Related]
36. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
37. The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma.
Mao Y; Cheng W; Yang Q; Li L; Hu W; Shuang Z; Fan D; Jiang X; Gao F; Li S; Wang W
Genomics; 2022 Jan; 114(1):95-106. PubMed ID: 34863899
[TBL] [Abstract][Full Text] [Related]
38. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
39. Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma.
Fang L; Chen S; Gong H; Xia S; Guan S; Quan N; Li Y; Zeng C; Chen Y; Du J; Liu S
Front Oncol; 2022; 12():1060508. PubMed ID: 36727081
[TBL] [Abstract][Full Text] [Related]
40. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
